Aptevo Therapeutics(APVO) - 2025 Q4 - Annual Results

Exhibit 99.1 Aptevo Provides State of the Business Report and 2025 Financial Results Highlights Aptevo entered 2026 with momentum: Latest mipletamig data delivers 86% clinical benefit rate with no cytokine release syndrome in 28 frontline AML patients, supporting its potential to enhance standard-of-care combination therapy Company expands CD3 pipeline and introduces first trispecific drug candidates SEATTLE, WA – March 26, 2026 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology compa ...